Shanghai-based Gestala, a burgeoning startup pioneering non-invasive ultrasound-based brain-computer interface (BCI) technology, has announced the successful closure of a $21.6 million (CN¥150 million) seed funding round, just two months after its official launch. This significant investment, which values the company between $100 million and $200 million, marks the largest early-stage funding in China’s rapidly accelerating BCI industry, signaling a potent challenge to established players and emerging innovators in the West, including Elon Musk’s Neuralink and OpenAI-backed Merge Labs. The round, co-led by prominent venture capital firms Guosheng Capital and Dalton Venture, saw robust participation from Tsing Song Capital, Gobi Ventures, Fourier Intelligence, Liepin, and Seas Capital. Founder and CEO Phoenix Peng revealed that the round was heavily oversubscribed, with investor commitments totaling more than $58 million, underscoring strong market confidence in Gestala’s vision and technological approach.
A New Force in the Global BCI Landscape
Gestala’s meteoric rise into the BCI spotlight is intrinsically linked to its founder, Phoenix Peng, a serial entrepreneur renowned in the Chinese tech scene. Peng is simultaneously spearheading another BCI venture, NeuroXess, which focuses on implantable BCI systems, mirroring the invasive approach championed by Neuralink. However, Gestala’s distinct focus on non-invasive ultrasound technology positions it uniquely in the global race for brain interface solutions. While the U.S. has seen several ultrasound BCI startups emerge in recent years, including Merge Labs, Gestala proudly stands as the first of its kind in China, injecting a new dynamic into the increasingly competitive BCI arena.
The newly secured capital is earmarked for aggressive expansion and rapid technological development. Peng outlined ambitious plans to significantly bolster Gestala’s research and development capabilities, expand its lean team from 15 to approximately 35 employees by the end of the year, and establish a state-of-the-art manufacturing facility within China. The immediate goal for the three-month-old startup is to complete its first-generation prototype by the close of 2026, a timeline that speaks to the urgency and speed characteristic of China’s deep-tech innovation ecosystem.
The Promise of Ultrasound: A Paradigm Shift in BCI?
The global BCI industry is currently experiencing a palpable surge in investment and research dedicated to ultrasound technology. For decades, BCI development has largely focused on two main categories: invasive systems requiring brain surgery to implant electrodes (offering high signal resolution but significant risks), and non-invasive systems like electroencephalography (EEG) that capture brain activity from outside the skull (safer but with lower spatial resolution). Ultrasound, however, presents a compelling middle ground, potentially offering the best of both worlds.
Phoenix Peng is a staunch advocate for ultrasound as the "next generation" of BCI technology. He envisions it unlocking unprecedented potential for broader, whole-brain access and entirely novel ways to interact with neural activity. The primary appeal of non-invasive ultrasound lies in its ability to circumvent one of the most substantial barriers to BCI adoption: the inherent risks associated with brain surgery. Surgical procedures, while offering unparalleled access to neural circuits, carry risks of infection, hemorrhage, and long-term complications, severely limiting their applicability to a broader patient population or healthy individuals seeking augmentation.
Compared to implanted electrode systems, ultrasound technology offers the distinct advantage of monitoring a larger portion of the brain, crucially including deep neural circuits that are challenging to access with surface electrodes. Utilizing phased-array ultrasound, the system can precisely stimulate or suppress neural activity without the need for any surgical intervention. This capability could dramatically expand the accessibility and safety profile of BCI technology, making it viable for a wider range of medical applications and potentially, consumer-grade devices in the future. The ability to non-invasively modulate deep brain regions could revolutionize treatments for various neurological and psychiatric disorders where current interventions are either highly invasive or ineffective.
A Global Race with Geopolitical Undercurrents
The rapid advancement of BCI technology, particularly by companies like Neuralink, Merge Labs in the U.S., and now Gestala and NeuroXess in China, highlights an intensifying global competition in deep technology. This race unfolds against a backdrop of rising geopolitical tensions between the United States and China, particularly concerning technological leadership and national security implications. Despite this challenging environment, Peng expresses a pragmatic hope for collaboration on deep-technology research between the two superpowers.
"Both countries bring different strengths," Peng stated, emphasizing a vision of complementary capabilities. He pointed out that "China offers large-scale clinical research capacity and efficient supply chains, while the U.S. has world-class scientific talent." This perspective suggests a recognition that combining these strengths could accelerate global neuroscience research, particularly in building large clinical datasets essential for training advanced AI models to interpret complex brain signals. Such a collaborative approach, if realized, could lead to breakthroughs that benefit humanity faster than isolated efforts, though the political climate makes such cross-border scientific partnerships increasingly complex. The implications of this are significant: while competition drives innovation, shared knowledge and resources could address global health challenges more effectively.
Targeting Critical Medical Needs: From Pain to Parkinson’s
Gestala’s immediate and long-term strategic focus is firmly rooted in medical applications, addressing conditions that affect vast populations globally. The startup’s lead program centers on chronic pain management, a condition that afflicts millions in both the U.S. and China, often leading to debilitating quality of life and significant healthcare burdens. Peng highlighted existing academic studies that suggest ultrasound stimulation can significantly reduce pain levels, offering a promising, non-pharmacological, and non-invasive alternative to current treatments. This focus is particularly astute, given the global opioid crisis and the pressing need for safer, more effective pain management solutions.
Beyond chronic pain, Gestala is actively exploring applications in mental health conditions, an area of growing global concern. This includes depression, post-traumatic stress disorder (PTSD), autism spectrum disorder, and obsessive-compulsive disorder (OCD). The non-invasive nature of ultrasound BCI could be particularly beneficial here, offering new therapeutic avenues without the stigma or invasiveness associated with brain surgery or even certain pharmaceutical interventions. The company is also investigating stroke rehabilitation, a critical area where early and effective intervention can significantly improve patient outcomes and quality of life.
Looking further ahead, Gestala has set its sights on longer-term targets, including neurodegenerative diseases such as Alzheimer’s disease, essential tremor, and Parkinson’s disease. In total, the company is researching six to eight potential indications. While most of these remain at the early research stage rather than in formal clinical trials, the breadth of its potential applications underscores the transformative promise of non-invasive ultrasound BCI. The ability to modulate specific brain regions implicated in these complex conditions, safely and repeatedly, could fundamentally change the landscape of neurological and psychiatric treatment.
China’s Integrated Ecosystem: Gestala’s Competitive Edge
Gestala posits that its advantage over global rivals stems from two key factors: speed and scale, both deeply rooted in China’s unique technological and manufacturing ecosystem. The startup believes it can leverage China’s highly integrated manufacturing infrastructure to move from development to production significantly faster than many international competitors. This efficiency in scaling production, often a bottleneck for deep-tech hardware startups, could give Gestala a critical lead in bringing its prototypes to market. China’s sophisticated supply chains and manufacturing capabilities are globally recognized, offering a significant strategic asset for hardware-intensive ventures.
Furthermore, Gestala is collaborating with major Chinese hospitals to accelerate clinical trials, a notoriously lengthy and expensive process in medical device development. The company estimates that these trials can be conducted at significantly lower costs in China—roughly 20% to 33% of comparable studies in the U.S. or Europe. This cost efficiency, combined with access to large patient populations, can dramatically shorten the time-to-market for medical devices, allowing Gestala to gather crucial efficacy and safety data more rapidly and economically.
Perhaps one of Gestala’s most strategic initiatives is the construction of what it terms an "Ultrasound Brain Bank." This ambitious project aims to build a massive clinical dataset of brain signals acquired via ultrasound BCI. The "Brain Bank" is designed to train advanced artificial intelligence (AI) models to accurately decode brain signals, which is fundamental for both precise BCI control and for supporting future neurological diagnostics. The creation of such a comprehensive dataset, especially with the unique characteristics of ultrasound data, could provide Gestala with a proprietary and significant competitive advantage in developing robust and intelligent BCI systems. It highlights a critical intersection of BCI, AI, and big data, positioning Gestala at the forefront of a data-driven approach to neuroscience.
Broader Implications and Future Outlook
Gestala’s record-breaking funding round is not merely a financial milestone; it is a profound indicator of the growing investor confidence in non-invasive BCI technologies and China’s escalating role as a leader in deep tech innovation. The BCI market, globally estimated to be worth several billion dollars and projected to grow substantially over the next decade (some reports suggest it could reach over $5 billion by 2027), is attracting significant capital and talent. This investment in Gestala underscores the potential for ultrasound BCI to capture a substantial share of this burgeoning market, particularly in medical applications where safety and accessibility are paramount.
The success of Gestala also signifies a broader trend in the BCI industry: while invasive solutions like Neuralink garner significant media attention for their audacious goals of human-computer symbiosis, non-invasive alternatives are quietly making substantial progress, potentially offering more immediate and widespread clinical benefits. The emphasis on chronic pain, mental health, and neurodegenerative diseases positions Gestala to address some of the most pressing global health challenges.
Looking ahead, the development pathway for BCI technology, especially for medical devices, remains long and complex, fraught with regulatory hurdles, ethical considerations, and the inherent challenges of understanding and interacting with the human brain. However, Gestala’s strategic approach—combining cutting-edge ultrasound technology, robust AI development, a focus on critical medical needs, and leveraging China’s manufacturing and clinical trial efficiencies—positions it as a formidable player in this transformative field. The global BCI race is accelerating, and with its recent funding, Gestala has clearly signaled its intent to be at the vanguard, pushing the boundaries of what’s possible in brain-computer interfaces and potentially reshaping the future of neuroscience and medicine. The world watches to see if this Chinese innovator can indeed deliver on its promise of a safer, more accessible, and more powerful way to connect with the human mind.
About the Author
